Please ensure Javascript is enabled for purposes of website accessibility

How Allergan Beat Estimates in What's Likely Its Last Quarterly Update

By Keith Speights - Feb 10, 2020 at 1:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker delivered solid top- and bottom-line improvement as it awaited the closing of its acquisition by AbbVie.

Allergan (AGN) entered 2020 with a lot of momentum. AbbVie's (ABBV 0.15%) announcement of its plans to acquire Allergan gave the stock a big boost. That news was so great that investors didn't care that Allergan delivered less-than-exciting third-quarter results in November.

But there were some things to energize investors in Allergan's 2019 fourth-quarter results, announced before the market opened on Monday. Here are the highlights from the company's Q4 update.

Dollar signs in pill packaging.

Image source: Getty Images.

By the numbers

Allergan reported revenue in the fourth quarter of $4.4 billion. This reflected a 6.6% increase from revenue of $4.08 billion generated in the prior-year period. The consensus Wall Street estimate projected Q4 revenue of $4.09 billion.

The company announced a net loss of $317.3 million, or $0.97 per share, based on generally accepted accounting principles (GAAP). However, this result showed significant improvement from the GAAP net loss of $4.3 billion, or $12.83 per share, posted in the same period in 2018. 

Allergan recorded adjusted earnings of $5.22 per share in the fourth quarter. This represented a 21.7% increase from adjusted earnings of $4.29 per share reported in the same quarter of 2019. Analysts were anticipating Q4 adjusted earnings of $4.57 per share.

Behind the numbers

The most important factor behind Allergan's revenue growth was the performance of its top-selling drug, Botox. Fourth-quarter sales for Botox jumped 7.9% year over year to $1.02 billion. 

But Allergan's fastest-rising star is definitely Vraylar. Sales for the antipsychotic drug skyrocketed 88.1% year over year in the fourth quarter to $283.1 million. 

Several of Allergan's other key drugs also generated solid sales growth. The company reported that Q4 sales of gastrointestinal drug Linzess/Constella rose by 12.5% to $238 million. Sales of Juvederm dermal fillers increased 4.5% year over year to $347.3 million.

The most notable weakness for Allergan in the fourth quarter was with chronic dry eye drug Restasis, with sales slipping 4.1% from the prior-year period to $327.7 million. In addition, several of the company's other products experienced significant sales declines, including Alphagan/Combigan, Asacol/Delzicol, and CoolSculpting.

Allergan's marked improvement in its GAAP bottom line stemmed mainly from the negative impact of a huge goodwill impairment in the fourth quarter of 2018. The company's non-GAAP adjusted earnings in the recent quarter were boosted by lower income tax adjustments than in the prior-year period.

Looking ahead

By far the main thing to look forward to with Allergan is the anticipated close of AbbVie's acquisition of the company later in the first quarter of 2020. This deal will make current Allergan shareholders owners in AbbVie, arguably one of the most attractive dividend stocks on the market right now.

However, there are also some pipeline milestones on the way in the near future. Allergan expects the FDA to make an approval decision in the first half of this year for sustained-release bimatoprost (Lumigan). An FDA decision on abicipar pegol in treating wet age-related macular degeneration is also expected in mid-2020, with European approval anticipated in the second half of the year.

Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Allergan plc Stock Quote
Allergan plc
AGN
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$140.55 (0.15%) $0.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.